Volume 42, Issue 5 p. 569-573

Using naltrexone implants in the management of the pregnant heroin user

G Hulse

Corresponding Author

G Hulse

Unit for Research and Education in Drugs and Alcohol University Department of Psychiatry and Behavioural Science, University of Western Australia, QE II Medical Centre King Edward Memorial Hospital Perth, Australia

Address for correspondence
Assoc Prof GK Hulse
Department of Psychiatry and Behavioural Science
University of Western Australia
Nedlands
Western Australia 6009 AustraliaSearch for more papers by this author
G O'Neil

G O'Neil

Unit for Research and Education in Drugs and Alcohol University Department of Psychiatry and Behavioural Science, University of Western Australia, QE II Medical Centre King Edward Memorial Hospital Perth, Australia

Unit for Research and Education in Drugs and Alcohol University Department of Psychiatry and Behavioural Science, University of Western Australia, QE II Medical Centre and the Australian Medical Procedures Research Foundation, Perth, Australia

Search for more papers by this author
First published: 28 October 2004
Citations: 48

G Hulse BBSC PhD, G O'Neill MBBS MRCOG FRACOG

Abstract

ABSTRACT

Objectives

To describe the case history and associated obstetric and neonatal outcomes of eight women who had their heroin dependency managed over pregnancy by naltrexone implant (two × 1.8 g of naltrexone embedded in poly-DL-lactide acid) treatment.

Method

Case data on maternal management associated with naltrexone implant were collected at the Australian Medical Procedures Research Foundation, Perth, Australia and three Perth hospitals.

Results

Despite earlier instability on oral naltrexone and repeated relapses back to dependent heroin use these women, following treatment with naltrexone implant, remained heroin free throughout their pregnancies. Neonatal and obstetric outcomes were unremarkable.

Conclusions

This case series provides preliminary evidence that the pregnant heroin user can be managed by naltrexone implant without obvious risk to the mother or developing foetus.

Importantly, the current case series suggests that the pregnant woman who finds it difficult to stabilise on oral naltrexone maintenance and returns to dependent heroin use may be managed using implantable naltrexone, thereby removing from her the onus for daily naltrexone medication compliance.

The authors conclude that naltrexone implant may represent an important procedure for managing the pregnant heroin dependent patient who finds it difficult to shift away from her heroin use patterns.

These preliminary findings require confirmation using a much larger controlled study.